• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Am J Prev Med. Author manuscript; available in PMC Mar 1, 2012.
Published in final edited form as:
PMCID: PMC3058636
NIHMSID: NIHMS266331

Smoker Characteristics and Smoking-Cessation Milestones

Abstract

Background

Contextual variables often predict long-term abstinence, but little is known about how these variables exert their effects. These variables could influence abstinence by affecting the ability to quit at all, or by altering risk of lapsing, or progressing from a lapse to relapse.

Purpose

To examine the effect of common predictors of smoking-cessation failure on smoking-cessation processes.

Methods

The current study (N = 1504, 58% female, 84% Caucasian; recruited from January 2005 to June 2007; data analyzed in 2009) uses the approach advocated by Shiffman et al., (2006), which measures cessation outcomes on three different cessation milestones (achieving initial abstinence, lapse risk, and the lapse-relapse transition) to examine relationships of smoker characteristics (dependence, contextual and demographic factors) with smoking-cessation process.

Results

High nicotine dependence strongly predicted all milestones: not achieving initial abstinence, and a higher risk of both lapse and transitioning from lapse to complete relapse. Numerous contextual and demographic variables were associated with higher initial cessation rates and/or decreased lapse risk at 6 months post-quit (e.g., ethnicity, gender, marital status, education, smoking in the workplace, number of smokers in the social network, and number of supportive others). However, aside from nicotine dependence, only gender significantly predicted the risk of transition from lapse to relapse.

Conclusions

These findings demonstrate that: (1) higher nicotine dependence predicted worse outcomes across every cessation milestone; (2) demographic and contextual variables are generally associated with initial abstinence rates and lapse risk and not the lapse-relapse transition. These results identify groups who are at risk for failure at specific stages of the smoking-cessation process, and this may have implications for treatment.

Introduction

Smoking-cessation research generally uses long-term abstinence to index the characteristics of a person associated with quitting success. However, Shiffman and colleagues1 suggested that long-term abstinence reflects multiple cessation processes,2,3 and successful cessation may depend on several components (“milestones”): achievement of short-term abstinence, avoidance of lapse, and if lapse occurs, avoidance of relapse.1 Parsing this multicomponent process into meaningful subunits may provide insight into the cessation process. The current study aims to advance understanding of the critical determinants of abstinence by relating smoker characteristics to cessation milestones.

Smoking-cessation Milestones

Shiffman and colleagues1 argued that smoking-cessation milestones may reflect different causal instigators and mechanisms. For instance, initial cessation may reflect the severity of the nicotine withdrawal syndrome.4 Lapsing often occurs in the presence of smoking cues and stressors, and may reflect the strength of associative processes or coping skills.49 The lapse-relapse transition may reflect nicotine dependence processes being primed or reinstated following a lapse.1012 Research has not systematically explored how smoker characteristics relate to cessation processes. The relationships between risk factors and milestones could provide insight into causes of cessation failure and suggest treatment strategies (e.g., by addressing risk factors for lapse-relapse progression for smokers who have lapsed).

Risk Factors for Cessation Failure

Research shows that cessation outcomes are affected by smoker characteristics and life context variables.1316 Theory and multivariate studies of relapse risk,1316, identified nicotine dependence, demographic, and life context variables as likely influences on cessation milestones.

Predicted Relationships

Based on research relating smoker characteristics with long-term abstinence, five contextual and five demographic variables were selected for analysis (contextual variables: home and work smoking bans,1721 smokers in the social network,2225 social support,24,2629 and stress,27,3034; demographic variables: marital status,35 gender,36 SES,3739 ethnicity,4042 and age,14,15,43). Many of the contextual and demographic variables used in this study predict encounters with key contexts, cues, and episodic events (stressors, strength of phasic affective reactions). For instance, the probability of exposure to smoking cues may be related to home and work smoking bans and smokers in the social network.4,4448 Other variables may predict exacerbation or buffering of episodic events such as stressor occurrence or affective reactions (e.g., social support24,26). Finally, several demographic variables may affect relapse because they are catchall indicators of both contextual risk and stress (e.g., SES, ethnicity,19,27,33,39,49,50). Because previous research,49, has linked lapses with particular contexts (e.g., social situations) and with episodic environmental challenges such as smoking cues, negative affect, and stressors,7 it was predicted that the contextual and demographic variables would be consistently associated with lapse likelihood. A further prediction was that nicotine dependence would be especially associated with initial cessation and the risk of lapse-relapse transition. This could be due, respectively to dependence-related withdrawal,2,4,51, and lapse-induced priming of dependence processes,11,52.

The Current Study

The current study uses clinical trial data53 to determine the relationship between smoker characteristics (nicotine dependence, demographics and life context) and the achievement of smoking-cessation milestones.

Methods

Participants

Participants were 1504 smokers (58% female, 83% Caucasian; Table 1) from Southeastern WI, participating in a clinical trial.53 Participants were recruited January 2005–June 2007; data were analyzed in 2009. Inclusion criteria were daily smoking (>9 cigarettes/day) and being motivated to quit. Exclusion criteria included medical contraindications to study medications, heavy alcohol consumption (≥6 drinks 6 days per week), or self-reported history of seizure, schizophrenia, psychosis, eating disorder, or bipolar disorder. Participants could not be pregnant or breastfeeding and agreed to use contraception. This study was approved by the University of Wisconsin IRB.

Table 1
Demographics and descriptive statistics

Procedure

Potential participants completed a phone screen. Those eligible attended an information session where they provided written, informed consent. Next, participants attended a screening visit to evaluate exclusion criteria. Additionally, participants completed demographic, smoking history, and tobacco dependence questionnaires. Eligible participants completed three baseline sessions occurring between 8 and 15 days pre-quit. Study visits occurred on the quit day, and 1, 2, 4 and 8 weeks post-quit.

Treatment

Double-blinded randomization, blocked on gender and ethnicity (Caucasian/non-Caucasian), assigned participants to one of six treatment conditions administered according to FDA guidelines: (1) bupropion SR (150 mg, bid for 9 weeks); (2) nicotine lozenge (2 or 4 mg, for 12 weeks); (3) nicotine patch (21, 14, and 7mg; titrated down over 8 weeks post-quit); (4) nicotine patch + nicotine lozenge combination therapy; (5) bupropion SR + nicotine lozenge combination therapy; or (6) placebo. There were five placebo conditions, matched to the active treatment conditions (e.g., placebo bupropion, lozenge, patch, patch + lozenge and bupropion + lozenge) that each constituted 1/5 of the placebo control group. All participants received six brief individual counseling sessions.

Smoking status

Daily smoking data were collected with a smoking calendar using timeline follow-back.54,55 The maximum amount of time for recall was 6 weeks. Seven-day point-prevalence abstinence was assessed during a 6-month follow-up call and biochemically confirmed (CO<10 ppm).

Milestone variables (Table 2)

Table 2
Definition of milestones and descriptive statistics

The three milestone variables were computed using smoking calendar data. The initial abstinence variable indicated whether participants reported smoking 0 cigarettes on at least 1 day in the first 14 days of the study. The lapse variable, coded for those who achieved initial abstinence, was the number of days between the first day where participants smoked zero cigarettes and the first day where they smoked any amount.1 Finally, the relapse variable, computed for participants who lapsed, was defined as the number of days from the lapse day until relapse (the first of 7 consecutive days of smoking).1 If participants did not reach a milestone (e.g., lapse/relapse), their milestone variable indicated the number of days from their last milestone until the end of follow-up. If they withdrew from the study before reaching a milestone, their milestone variable indicated the number of days from their last milestone until their withdrawal date.

Demographics and Smoking History

A demographics questionnaire measured gender, ethnicity (Caucasian vs non-Caucasian), marital status (married/domestic partner vs divorced/separated/widowed/never married), educational attainment (< vs ≥4-year college degree), and age. A smoking-history questionnaire assessed smoking restrictions at home (yes vs no) and work (total work smoking ban vs partial ban/no ban/not working outside the home).

The Fagerström Test of Nicotine Dependence

The FTND56 is made up of six items with scores ranging from 0 to 10; higher scores indicate greater dependence.

Social Network Interview

Participants listed up to nine people who provided emotional support, instrumental support, or who were “important” to them over the past year. One additional name was allowed if participants had a romantic partner. Network sizes varied from 0 to 10. The interview assessed the amount of emotional support network members provided, the amount of stress they caused, and their smoking. The number of smokers in the network included daily or social smokers. The number of network members providing social support included members who provided a little, a medium amount, or a lot of support.

Social Readjustment Rating scale (SRRS)

The SRRS is a life events checklist of the number of stressful life events reported in the past year.57

Data Analysis

Tests of milestones

Analyses were conducted using SAS 9.2, controlling for treatment. Treatment was dummy-coded with placebo as the comparison group. Analyses of initial and point-prevalence abstinence used logistic regression (abstinence=0). Analyses of lapse and relapse used Cox proportional hazards regression survival analysis. Individuals were censored at the time of their last contact if they did not have an event (e.g., lapse, relapse). In the survival analyses having an event (e.g., lapse, relapse) was coded as “0”. Analyses (except initial abstinence) were conducted using the 6-month follow-up period. Unless otherwise noted, results were significant after a Holm alpha correction.58 Models were examined for multicollinearity.

Interactions with treatment period

To determine whether the effects of smoker characteristics varied throughout the quit attempt, interactions with treatment period (8 weeks) were examined for survival analyses. For the lapse analyses, the results of the hazard function during treatment versus after treatment were compared by computing the interaction between the independent variable and a variable representing during versus after treatment. For the relapse analyses, the effects of treatment in individuals who had and had not relapsed during treatment were compared by computing a variable signifying relapsing during treatment (relapse during treatment = 1). Then a model was tested that included the independent variable, the relapsed during treatment variable, and the product of the two. Only significant interactions with treatment period are reported.

Interactions with treatment condition

Interactions between risk variables and medication condition were examined: none was significant after alpha correction (main effects of treatment on milestones are presented in a separate paper59).

Results

Achievement of milestones

Of the 1504 smokers in the study, 1429 (95.0%) had complete calendar data for the first 14 days. Of those 1429, a total of 1259 achieved initial abstinence (88.1%) (median=0 days). Of the 1259 who achieved initial abstinence, 930 lapsed (73.9%) (median = 7 days). Of those 930 who lapsed, 585 relapsed (62.9%) (median days to relapse =38; median days from lapse to relapse =15; Table 2).

Reporting of results

Main effects and alpha-corrected significance levels are presented in Table 3.

Table 3
Univariate analyses (controlling for treatment) of dependence, context and demographic variables predicting smoking-cessation milestones

Nicotine Dependence

Those with higher FTND scores were less likely to be abstinent at 6-month follow-up, achieve initial abstinence, and had higher lapse and lapse–relapse risk.

Demographics

Education

College-educated individuals were more likely to be abstinent at 6-month follow-up, achieve initial abstinence, and have lower lapse risk than those without a college education. Education was not significantly associated with lapse–relapse risk.

Marital Status

Marital status analyses controlled for partner smoking status. Those who were partnered were more likely to be abstinent at 6-month follow-up and had a lower lapse risk. Marital status was not significantly associated with initial abstinence or lapse–relapse risk.

Gender

Women were less likely to be abstinent at 6-month follow-up, had higher lapse and lapse–relapse risk. Gender was not associated with initial abstinence. Gender was more strongly related to the lapse–relapse risk after treatment than during treatment (HR = 1.64, p = .01, 95% CI = 1.11, 2.42).

Age

Age did not predict point-prevalence abstinence or milestones.

Ethnicity

Caucasians had higher abstinence rates at 6-month follow-up, higher initial abstinence rates and a lower lapse risk and than did non-Caucasians. Ethnicity was not significantly associated with lapse–relapse risk.

Contextual Variables

Smoking in the home

Those without a home smoking ban were less likely to achieve initial abstinence, had lower abstinence rates at 6-month follow-up, and higher lapse risk than those with a ban. Home smoking bans were not associated with lapse–relapse risk.

Smoking at work

Those without work smoking bans were less likely to be abstinent at 6-month follow-up and had higher lapse risk than those with bans. Work smoking bans were not significantly associated with initial abstinence or lapse–relapse risk.

Stress Response Rating Scale (SRRS)

Those with higher scores on the SRRS were less likely to achieve initial abstinence (not significant after alpha correction). The SRRS was not significantly associated with 6-month abstinence, lapse or lapse–relapse risk.

Proportion of smokers in the social network

These analyses controlled for the total network size. Those with a larger proportion of smokers in the social network were less likely to be abstinent at 6-month follow-up (not significant after alpha correction) and had a higher lapse risk. The proportion of smokers in the social network was not significantly associated with achievement of initial abstinence or lapse–relapse risk.

Number of supportive individuals in the social network

The number of supportive individuals in the social network was not corrected for network size. Those with more supportive individuals were more likely to achieve initial abstinence. Number of supportive individuals was not significantly associated with 6-month abstinence, lapse risk or lapse–relapse risk. The number of supportive individuals was more strongly related to lapse–relapse risk during the 8-week treatment period than during the post-treatment period (HR = 1.12, p =.01, 95% CI = 1.03, 1.22); number of supportive individuals predicted lapse–relapse risk during the treatment period (HR = .92, p =.002, 95% CI = 0.88, 0.97) but not during the follow-up period (p>0.05).

Multiple Regression Models

Multivariable models were tested where all dependence, demographic and contextual variables were entered into multivariable logistic regressions and survival analyses (controlling for treatment; see Table 4).

Table 4
Multiple regression models including dependence, demographic, contextual variables and treatment

Point-prevalence abstinence

Significant predictors of 6-month point-prevalence abstinence were: FTND, age, gender, and education.

Initial abstinence

Significant predictors of initial abstinence were: FTND, ethnicity, and smoking in the home.

Lapse

Significant predictors of lapse risk were: ethnicity, gender, marital status, education, smoking at work, number of smokers in the social network, and number of supportive individuals in the social network.

lapse–relapse transition

Significant predictors of lapse–relapse risk were: FTND and gender.

Discussion

Consistent with hypotheses, nicotine dependence was associated with decreased rates of initial cessation, and higher risk of transitioning from lapse to relapse, independent of demographic and life context factors. This is consistent with Edwards' (1975) theory that rapid reinstatement of drug use is a hallmark of dependence.60 Nicotine dependence was related to lapse risk when tested alone, but not in multivariate models. This suggests that nicotine dependence has some relationship to the lapsing process (e.g., perhaps indexing conditioned responses to smoking cues), but does not have unique predictive validity (Table 4). Thus, the data suggest that dependence influences ultimate cessation outcome because it affects withdrawal, which in turn thwarts initial abstinence, and because lapses deliver priming doses of nicotine, which reinstate important dependence processes and spur relapse.52,61

Demographic and contextual variables

While not predicted, many of the demographic and contextual variables predicted the achievement of initial abstinence, with ethnicity and smoking in the home making unique contributions. Consistent with predictions, all of the demographic and contextual variables were significantly related to lapse risk with the exception of smoking in the home and life stress. Smoking in the home, however, was found to have a very strong relationship with initial abstinence. Therefore, it is possible that those at greatest risk due to smoking in the home failed to quit and were unavailable to lapse. Stress may have been unrelated to lapse risk because the measure of stress (SSRS57) was retrospective, and therefore insensitive to stress during the quit attempt.7 To the extent that the demographic and contextual variables coded for greater exposure to high-risk contexts and phasic events (e.g., smoking cues, stressors, negative affect), the current findings are generally consistent with previous research that characterizes the episodic and contextual nature of such risk.7 The results also show that contextual and demographic variables tend to decrease the likelihood of initial abstinence. The current data do not suggest a mechanism for these effects, but candidates could be cue-induced conditioned reactions, which might be exacerbated by withdrawal.4,5,9,62

Surprisingly, gender was the only demographic or contextual variable to make a significant and unique contribution to risk of relapse (with women having a 29% greater risk of relapse than men; Table 3). Gender effects on long-term abstinence have been reported frequently, but little is known about how or when such effects are manifested. These results suggest that women quit at the same rate as men, but are more likely than men to sample cigarettes and thereafter escalate their use. It was predicted that social support would predict relapse risk. While social support was related to initial abstinence and lapse risk, it was significantly associated with relapse risk only during treatment. Marital status, a less direct measure of social support, failed to predict relapse.

There could be several reasons for the failure of contextual and demographic factors to predict relapse. It may be that the motivational forces unleashed by a lapse dwarf the importance of contextual and demographic influences. Previous research has found that the vast majority of individuals who lapse eventually relapse; perhaps severe dependence renders relapse, given a lapse, almost inevitable.51 It could also be that contextual and demographic predictors of the risk of progressing from lapse to relapse exist, and were not adequately sampled in this research.

Summary and Implications

Nicotine dependence appeared to affect all cessation milestones, and especially initial abstinence and the transition from lapse to relapse. Thus, the treatments most likely to reduce lapse–relapse transitions might be those that counter dependence-related mechanisms unleashed by lapse cigarettes (e.g., increasing nicotine replacement dose after lapse).

Most demographic and contextual variables appeared to affect early milestones such as achievement of initial abstinence and lapse, but not the lapse–relapse transition. This may explain why the two most effective counseling elements are cue avoidance/coping training and intratreatment support,63 as these treatment elements may address threats to initial abstinence and lapse occurrence. These treatments may be less effective for relapse prevention,3, to the extent that the nature of the risks changes after a lapse being more associated with gender and dependence.

These findings identify populations at risk for failure at each of the cessation milestones. Contextual and demographic variables reflecting environmental smoking exposure (smoking in the home), life stress and low levels of social support seem particularly detrimental for individuals trying to achieve initial abstinence and avoid lapsing. Therefore, treatments focusing on such risk variables could be offered to these populations at elevated risk24 Finally, amongst the demographic and contextual variables, gender was uniquely and strongly related to lapse–relapse transition. This should encourage research to uncover causes or mediators of the extra risk experienced by women.27

Limitations and future directions

One limitation of this research is that contextual variables were measured via retrospective questionnaires rather than real-time data acquisition methods. Future research could use these methods to examine whether stronger relationships are found between context and milestones when contextual features are measured in real time (but this would lack some clinical utility for risk assessment). In addition, real-time data could be used to test the mechanisms by which smoker characteristics affect milestone outcomes. Second, the method of examining milestones for only those individuals who reached a previous milestone certainly affects the variables that are related to later milestones. For instance, the rate of lapsing affects the type of smoker who is “available” for relapse, which no doubt affects patterns of relationships with relapse predictors. In addition, this group is somewhat unrepresentative of the general population, limiting generalizability.

Acknowledgements

This research was conducted at the University of Wisconsin-Madison and was supported by grant #P50 DA019706 from NIH/NIDA; by grant #M01 RR03186 from the General Clinical Research Centers Program of the National Center for Research Resources, NIH; by an Institutional Clinical and Translational Science Award (UW-Madison; KL2 Grant # 1KL2RR025012-01); and by grant #s 1K05CA139871 and K08DA025041 from the NIH. Medication was provided to participants at no cost under a research agreement with GlaxoSmithKline (GSK); no part of this manuscript was written or edited by anyone employed by GSK. The authors are solely responsible for the analyses, content, and writing of this article. The authors have full control of all primary data, and they agree to allow the journal to review the data if requested.

TBB has served as an investigator on research projects sponsored by pharmaceutical companies including Pfizer, Glaxo Wellcome, Sanofi, and Nabi. Over the past 3 years, MCF has served as an investigator in research studies at the University of Wisconsin that were funded by Pfizer, GlaxoSmithKline and Nabi Biopharmaceuticals.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

No other authors reported financial disclosures.

References

1. Shiffman S, Scharf DM, Shadel WG, Gwaltney CJ, Dang Q, Paton SM, Clark DB. Analyzing milestones in smoking cessation: Illustration in a nicotine patch trial in adult smokers. J Consult Clin Psychol. 2006 Apr;74(2):276–285. [PubMed]
2. Piasecki TM. Relapse to smoking. Clin Psychol Rev. 2006 Mar;26(2):196–215. [PubMed]
3. Piasecki TM, Fiore MC, McCarthy DE, Baker TB. Have we lost our way? the need for dynamic formulations of smoking relapse proneness. Addiction (Abingdon, England) 2002 Sep;97(9):1093–1108. [PubMed]
4. McCarthy DE, Piasecki TM, Fiore MC, Baker TB. Life before and after quitting smoking: An electronic diary study. J Abnorm Psychol. 2006 Aug;115(3):454–466. [PubMed]
5. Caggiula AR, Donny EC, Chaudhri N, Perkins KA, Evans-Martin FF, Sved AF. Importance of nonpharmacological factors in nicotine self-administration. Physiol Behav. 2002 Dec;77(4–5):683–687. [PubMed]
6. Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, Hoffman A, Perkins KA, Sved AF. Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav. 2001 Dec;70(4):515–530. [PubMed]
7. Shiffman S, Gnys M, Richards TJ, Paty JA, Hickcox M, Kassel JD. Temptations to smoke after quitting: A comparison of lapsers and maintainers. Health Psychol. 1996 Nov;15(6):455–461. [PubMed]
8. Conklin CA. Environments as cues to smoke: Implications for human extinction-based research and treatment. Exp Clin Psychopharmacol. 2006 Feb;14(1):12–19. [PubMed]
9. Conklin CA, Robin N, Perkins KA, Salkeld RP, McClernon FJ. Proximal versus distal cues to smoke: The effects of environments on smokers' cue-reactivity. Exp Clin Psychopharmacol. 2008 Jun;16(3):207–214. [PMC free article] [PubMed]
10. Baker TB, Japuntich SJ, Hogle JM, McCarthy DE, Curtin JJ. Pharmacologic and behavioral withdrawal from addictive drugs. Current Directions in Psychological Science. 2006;5(5):232–236.
11. Chiamulera C, Borgo C, Falchetto S, Valerio E, Tessari M. Nicotine reinstatement of nicotine self-administration after long-term extinction. Psychopharmacology. 1996 Sep;127(2):102–107. [PubMed]
12. Robinson TE, Berridge KC. Addiction. Annu Rev Psychol. 2003;54:25–53. [PubMed]
13. Bolt DM, Piper ME, McCarthy DE, Japuntich SJ, Fiore MC, Smith SS, Baker TB. The wisconsin predicting patients' relapse questionnaire. Nicotine & Tobacco Research. 2009 May;11(5):481–492. [PMC free article] [PubMed]
14. Nides MA, Rakos RF, Gonzales D, Murray RP, Tashkin DP, Bjornson-Benson WM, Lindgren P, Connett JE. Predictors of initial smoking cessation and relapse through the first 2 years of the lung health study. J Consult Clin Psychol. 1995 Feb;63(1):60–69. [PubMed]
15. Osler M, Prescott E. Psychosocial, behavioural, and health determinants of successful smoking cessation: A longitudinal study of danish adults. Tob Control. 1998 Autumn;7(3):262–267. [PMC free article] [PubMed]
16. Richmond RL, Kehoe LA, Webster IW. Multivariate models for predicting abstention following intervention to stop smoking by general practitioners. Addiction (Abingdon, England) 1993 Aug;88(8):1127–1135. [PubMed]
17. Bauer JE, Hyland A, Li Q, Steger C, Cummings KM. A longitudinal assessment of the impact of smoke-free worksite policies on tobacco use. Am J Public Health. 2005 Jun;95(6):1024–1029. [PMC free article] [PubMed]
18. Brownson RC, Hopkins DP, Wakefield MA. Effects of smoking restrictions in the workplace. Annu Rev Public Health. 2002;23:333–348. [PubMed]
19. Chandola T, Head J, Bartley M. Socio-demographic predictors of quitting smoking: How important are household factors? Addiction (Abingdon, England) 2004 Jun;99(6):770–777. [PubMed]
20. Farrelly MC, Evans WN, Sfekas AE. The impact of workplace smoking bans: Results from a national survey. Tob Control. 1999 Autumn;8(3):272–277. [PMC free article] [PubMed]
21. Pizacani BA, Martin DP, Stark MJ, Koepsell TD, Thompson B, Diehr P. A prospective study of household smoking bans and subsequent cessation-related behaviour: The role of stage of change. Tob Control. 2004 Mar;13(1):23–28. [PMC free article] [PubMed]
22. Christakis NA, Fowler JH. The collective dynamics of smoking in a large social network. The N Engl J Med. 2008 May 22;358(21):2249–2258. [PMC free article] [PubMed]
23. Homish GG, Leonard KE. Spousal influence on smoking behaviors in a U.S. community sample of newly married couples. Soc Sci Med (1982) 2005 Dec;61(12):2557–2567. [PMC free article] [PubMed]
24. Mermelstein R, Cohen S, Lichtenstein E, Baer JS, Kamarck T. Social support and smoking cessation and maintenance. J Consult Clin Psychol. 1986 Aug;54(4):447–453. [PubMed]
25. Morgan GD, Ashenberg ZS, Fisher EB., Jr. Abstinence from smoking and the social environment. J of Consult Clin Psychol. 1988 Apr;56(2):298–301. [PubMed]
26. Hanson BS, Isacsson SO, Janzon L, Lindell SE. Social support and quitting smoking for good. is there an association? results from the population study, “men born in 1914,” malmo, sweden. Addict Behav. 1990;15(3):221–233. [PubMed]
27. McKee SA, Maciejewski PK, Falba T, Mazure CM. Sex differences in the effects of stressful life events on changes in smoking status. Addiction. 2003 Jun;98(6):847–855. [PubMed]
28. McMahon SD, Jason LA. Social support in a worksite smoking intervention. A test of theoretical models. Behav Modif. 2000 Apr;24(2):184–201. [PubMed]
29. Steptoe A, Wardle J, Pollard TM, Canaan L, Davies GJ. Stress, social support and health-related behavior: A study of smoking, alcohol consumption and physical exercise. J Psychosom Res. 1996 Aug;41(2):171–180. [PubMed]
30. Falba T, Teng HM, Sindelar JL, Gallo WT. The effect of involuntary job loss on smoking intensity and relapse. Addiction. 2005 Sep;100(9):1330–1339. [PMC free article] [PubMed]
31. Kouvonen A, Kivimaki M, Virtanen M, Pentti J, Vahtera J. Work stress, smoking status, and smoking intensity: An observational study of 46,190 employees. J Epidemiol Community Health. 2005 Jan;59(1):63–69. [PMC free article] [PubMed]
32. Manning BK, Catley D, Harris KJ, Mayo MS, Ahluwalia JS. Stress and quitting among african american smokers. J Behav Med. 2005 Aug;28(4):325–333. [PubMed]
33. Siahpush M, Carlin JB. Financial stress, smoking cessation and relapse: Results from a prospective study of an australian national sample. Addiction. 2006 Jan;101(1):121–127. [PubMed]
34. Tate SR, McQuaid JR, Brown SA. Characteristics of life stressors predictive of substance treatment outcomes. J Subst Abuse Treat. 2005 Sep;29(2):107–115. [PubMed]
35. Derby CA, Lasater TM, Vass K, Gonzalez S, Carleton RA. Characteristics of smokers who attempt to quit and of those who recently succeeded. Am J Prev Med. 1994 Nov–Dec;10(6):327–334. [PubMed]
36. Perkins KA. Smoking cessation in women. special considerations. CNS Drugs. 2001;15(5):391–411. [PubMed]
37. Fernandez E, Schiaffino A, Borrell C, Benach J, Ariza C, Ramon JM, Twose J, Nebot M, Kunst A. Social class, education, and smoking cessation: Long-term follow-up of patients treated at a smoking cessation unit. Nicotine & Tobacco Research. 2006 Feb;8(1):29–36. [PubMed]
38. Levy DT, Romano E, Mumford E. The relationship of smoking cessation to sociodemographic characteristics, smoking intensity, and tobacco control policies. Nicotine & Tobacco Research. 2005 Jun;7(3):387–396. [PubMed]
39. Siahpush M, Heller G, Singh G. Lower levels of occupation, income and education are strongly associated with a longer smoking duration: Multivariate results from the 2001 australian national drug strategy survey. Public Health. 2005 Dec;119(12):1105–1110. [PubMed]
40. Doolan DM, Froelicher ES. Efficacy of smoking cessation intervention among special populations: Review of the literature from 2000 to 2005. Nurs Res. 2006 Jul–Aug;55(4 Suppl):S29–37. [PubMed]
41. Pederson LL, Ahluwalia JS, Harris KJ, McGrady GA. Smoking cessation among african americans: What we know and do not know about interventions and self-quitting. Prev Med. 2000 Jul;31(1):23–38. [PubMed]
42. USDHHS . Tobacco use among U.S. racial/ethnic minority groups. CDC, National Center for Chronic Disease and Health Prevention and Health Promotion, Office of Smoking and Health; Atlanta, GA: 1998.
43. Nides M, Glover ED, Reus VI, Christen AG, Make BJ, Billing CB, Jr, Williams KE. Varenicline versus bupropion SR or placebo for smoking cessation: A pooled analysis. Am J Health Behav. 2008 Nov–Dec;32(6):664–675. [PubMed]
44. Kassel JD, Stroud LR, Paronis CA. Smoking, stress, and negative affect: Correlation, causation, and context across stages of smoking. Psychol Bull. 2003 Mar;129(2):270–304. [PubMed]
45. Fergusson DM, Goodwin RD, Horwood LJ. Major depression and cigarette smoking: Results of a 21-year longitudinal study. Psychol Med. 2003 Nov;33(8):1357–1367. [PubMed]
46. Ferguson SG, Shiffman S, Gwaltney CJ. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol. 2006 Dec;74(6):1153–1161. [PubMed]
47. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Baker TB. Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction. 2008 Sep;103(9):1521–1533. [PMC free article] [PubMed]
48. Piper ME, Federmen EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, Baker TB. Using mediational models to explore the nature of tobacco motivation and tobacco treatment effects. J of Abnorm Psychol. 2008 Feb;117(1):94–105. [PubMed]
49. Honjo K, Tsutsumi A, Kawachi I, Kawakami N. What accounts for the relationship between social class and smoking cessation? results of a path analysis. Soc Sci Med (1982) 2006 Jan;62(2):317–328. [PubMed]
50. De Vogli R, Santinello M. Unemployment and smoking: Does psychosocial stress matter? Tob Control. 2005 Dec;14(6):389–395. [PMC free article] [PubMed]
51. Kenford SL, Smith SS, Wetter DW, Jorenby DE, Fiore MC, Baker TB. Predicting relapse back to smoking: Contrasting affective and physical models of dependence. J Consultand Clin Psychol. 2002 Feb;70(1):216–227. [PubMed]
52. Dravolina OA, Zakharova E,S, Shekunova EV, Danysz W, Bepspalov AY. mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats. Neuropharmacology. 2007;52(2):263–269. [PubMed]
53. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, Baker TB. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009 Nov;66(11):1253–1262. [PMC free article] [PubMed]
54. Brigham J, Lessov-Schlaggar CN, Javitz HS, McElroy M, Krasnow R, Swan GE. Reliability of adult retrospective recall of lifetime tobacco use. Nicotine & Tobacco Research. 2008 Feb;10(2):287–299. [PubMed]
55. Sobell LC, Sobell MB, Leo GI, Cancilla A. Reliability of a timeline method: Assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. British Journal of Addiction. 1988 Apr;83(4):393–402. [PubMed]
56. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The fagerstrom test for nicotine dependence: A revision of the fagerstrom tolerance questionnaire. British Journal of Addiction. 1991 Sep;86(9):1119–1127. [PubMed]
57. Holmes TH, Rahe RH. The social readjustment rating scale. J Psychosom Res. 1967 Aug;11(2):213–218. [PubMed]
58. Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics. 6:65–70.
59. Japuntich SJ, Piper ME, Leventhal AM, Bolt DM, Baker TB. The effect of five smoking cessation pharmacotherapies on smoking cessation milestones. J Consult Clin Psychol. In press. [PMC free article] [PubMed]
60. Edwards G. The meaning and treatment of alcohol dependence. Br J Psychiatry. 1975;9:239–251. [PubMed]
61. Herd N, Borland R, Hyland A. Predictors of smoking relapse by duration of abstinence: Findings from the international tobacco control (ITC) four country survey. Addiction. 2009;104(12):2088–2099. [PubMed]
62. Gloria R, Angelos L, Schaefer HS, Davis JM, Majeskie M, Richmond BS, Curtin JJ, Davidson RJ, Baker TB. An fMRI investigation of the impact of withdrawal on regional brain activity during nicotine anticipation. Psychophysiology. 2009;46:681–693. [PMC free article] [PubMed]
63. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. clinical practice guideline. 2008 May; May 2008;June 27, 2008.
64. Kozlowski LT, Porter CQ, Orleans CT, Pope MA, Heatherton T. Predicting smoking cessation with self-reported measures of nicotine dependence: FTQ, FTND and HSI. Drug Alcohol Depend. 1994;34:211–216. [PubMed]
65. Transdisciplinary Tobacco Use Research Center (TTURC) Tobacco Dependence. Baker TB, Piper ME, McCarthy DE, Bolt DM, Smith SS, Kim SY, Colby S, Conti D, Giovino GA, Hatsukami D, Hyland A, Krishnan-Sarin S, Niaura R, Perkins KA, Toll BA. Time to first cigarette in the morning as an index of ability to quit smoking: Implications for nicotine dependence. Nicotine & Tobacco Research. 2007 Nov;9(Suppl 4):S555–70. [PMC free article] [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...